Puja P Khanna, MD, MPH
Clinical Professor of Internal Medicine
Service Chief, Internal Medicine
[email protected]

Available to mentor
Puja P Khanna, MD, MPH
Clinical Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Journal Article
      P084 Gout symptom improvements and patient outcomes with SEL-212 in gout refractory to conventional therapy: DISSOLVE I & II phase 3, double-blind, placebo-controlled clinical trials
      Baraf HSB, Khanna P, Patel A, Sobierska J, Christie J, DeHaan W, Azeem R, Traber PG, Kivitz A. Rheumatology, 2024 Apr 24; 63 (Supplement_1): keae163.125 DOI:10.1093/rheumatology/keae163.125
    • Journal Article
      The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
      Baraf HSB, Khanna PP, Kivitz AJ, Strand V, Choi HK, Terkeltaub R, Dalbeth N, DeHaan W, Azeem R, Traber PG, Keenan RT. Rheumatology (Oxford), 2024 Apr 2; 63 (4): 1058 - 1067. DOI:10.1093/rheumatology/kead333
      PMID: 37449908
    • Journal Article
      Artificial intelligence in rare disease diagnosis and treatment.
      Wojtara M, Rana E, Rahman T, Khanna P, Singh H. Clin Transl Sci, 2023 Nov; 16 (11): 2106 - 2111. DOI:10.1111/cts.13619
      PMID: 37646577
    • Journal Article
      Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
      Khanna D, Padilla C, Tsoi LC, Nagaraja V, Khanna PP, Tabib T, Kahlenberg JM, Young A, Huang S, Gudjonsson JE, Fox DA, Lafyatis R. JCI Insight, 2022 Sep 8; 7 (17): DOI:10.1172/jci.insight.159566
      PMID: 35943798
    • Proceeding / Abstract / Poster
      OP0169 INPATIENT DISCONTINUATION OF ALLOPURINOL – A QUALITATIVE IMPROVEMENT (QI) INITIATIVE
      Farshad S, Ramahi A, Murphy A, Aleatany Y, Khanna P. Annals of the Rheumatic Diseases, 2022 Jun; 81 (Suppl 1): 111 - 112. DOI:10.1136/annrheumdis-2022-eular.2983
    • Proceeding / Abstract / Poster
      OP0170 PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF A TRANSDERMAL ALKALINIZING AND PAIN-RELIEVING TREATMENT FOR REDUCING PAIN ASSOCIATED WITH AN ACUTE GOUT FLARE
      Khanna P, Beal R. Annals of the Rheumatic Diseases, 2022 Jun; 81 (Suppl 1): 112.2 - 11112. DOI:10.1136/annrheumdis-2022-eular.4909
    • Journal Article
      Remission in Gout: Concepts From a Patient Perspective.
      Khanna P. J Rheumatol, 2022 Mar; 49 (3): 242 - 243. DOI:10.3899/jrheum.211285
      PMID: 35034002
    • Proceeding / Abstract / Poster
      The Impact of Topically Applied pH Modulator on Acute Inflammatory Pain, Serum Calcium, and C-Reactive Protein (CRP) During an Acute Gout Flare - a Phase 2a Randomized, Double-Blind, Placebo-Controlled Study
      Khanna P, Beal R. ARTHRITIS & RHEUMATOLOGY, 2022 74: 3529 - 3531.